Skip to main content

NCT06062069

CT-868-004
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Mellitus

Icon for trial | CT-868-004 CT-868-004
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Me

This study is currently enrolling.

Study Purpose: To evaluate the safety and tolerability of the study drug, CT-868, and to study the effect that CT-868 has on Type 1 Diabetes and weight. To be enrolled in this study, you must meet certain requirements. You may ...

NCT05076175

A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inadequate Response to Conventional Therapy

Icon for trial | IM047-001 A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inade

This study is currently enrolling.

You are being asked to take part in this study because you have been diagnosed with or have symptoms of moderately to severely active ulcerative colitis (UC). UC is a chronic inflammatory disorder of the bowels. People with UC ...

NCT05948865

CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors

Icon for trial | CPO301-US-101 CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Adv

This study is currently enrolling.

The purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into the vein) infusion (IV) ov ...

Subscribe to